Relmada Therapeutics 

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology firm, concentrating its efforts on developing various therapeutic solutions for ailments affecting the central nervous system (CNS) and other disorders. The company's primary drug candidate is Esmethadone (also known as d-methadone, dextromethadone, or REL-1017), a novel chemical compound. This N-methyl-D-aspartate receptor antagonist is currently undergoing Phase 3 clinical trials, investigating its efficacy as both a supplementary and standalone treatment for major depressive disorder in adult patients. Founded in 2004, the enterprise maintains its corporate headquarters in Coral Gables, Florida.